Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

Presence of KEVs, KEVs Linked to Ransomware, and Insecure Internet Exposure Found to be Pervasive Among BMS, BAS According to ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for $13 billion in 2020 – will launch under the Camzyos brand name with a list price of $89,500 per year.

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

Burrows sees the benefits of such partnerships every day at the GDMS–UK facility in Oakdale, South Wales. The company is ...

A high-tech e-bike will give you a fully digital dashboard. You can see your current speed, total distance, battery life, and ...

A refreshed version of the Tesla Semi was seen testing outside the Semi pilot manufacturing facility in Nevada. And what is ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $25 Call had some of the highest ...

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine ...